Skip to content
value.today

Oculeve, Inc.

Total raised
$24 M
2 rounds on record
Latest round
$17 M
Mar 2014
First round on record
Oct 2012
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Oculeve, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2014$17 MNo. 2$10 to $50 million

Oculeve, Inc.: Raise no. 2, Mar 2014

Investors in this round

8 investors had bought by the notice of Mar 18, 2014: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • D. Michael Ackermann, PhD · Executive Officer, Director
  • James J. Loudin · Executive Officer
  • Ali Behbahani · Director
  • Brook S. Byers · Director
  • Mark S. Blumenkranz, MD · Director
  • Steve J. Waite · Director
  • William J. Link, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Actual Total Offering Amount: $16,649,997.99 Actual Total Amount Sold: $16,649,997.99”

Signed by D. Michael Ackermann, PhD, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 18, 2014. Read the notice at the SEC.

equitySEC
Oct 2012$8 MNo. 1$2 to $10 million

Oculeve, Inc.: Raise no. 1, Oct 2012

Investors in this round

9 investors had bought by the notice of Mar 20, 2013: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • D. Michael Ackermann, PhD · Executive Officer, Director
  • Ali Behbahani · Director
  • Brook Byers · Director
  • Mark Blumenkranz · Director
  • William Link · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by D. Michael Ackermann, PhD, President. Source: SEC Form D and 1 amendment, newest notice filed Mar 20, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Oculeve, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2014).

    SEC Form D · Mar 2014

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Mar 2014

That is all the official record says: Oculeve, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Oculeve, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Oculeve, Inc.
NameRoleNamed in
D. Michael Ackermann, PhDExecutive officerMar 2014
James J. LoudinExecutive officerMar 2014
Ali BehbahaniDirectorMar 2014
Brook S. ByersDirectorMar 2014
D. Michael Ackermann, PhDDirectorMar 2014
Mark S. Blumenkranz, MDDirectorMar 2014
Steve J. WaiteDirectorMar 2014
William J. Link, PhDDirectorMar 2014
Brook ByersDirectorMar 2013
Mark BlumenkranzDirectorMar 2013
William LinkDirectorMar 2013